Pharma / Biotech

Keytruda Approved for Recurrent or Metastatic Cutaneous Squamous Cell Cancer



The FDA approved pembrolizumab (Keytruda, Merck) for patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation. 

Source link

Related posts

PHENTERMINE HYDROCHLORIDE Capsule [Bryant Ranch Prepack]

Newsemia

clinical pharmacology; +200 new citations

Newsemia

SODIUM SULFACETAMIDE Liquid [BioComp Pharma, Inc.]

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World